# Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

> **NCT06948786** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 22 (estimated)

## Conditions studied

- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **BIOLOGICAL:** Mosunetuzumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06948786
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2031-07-31
- **Final completion:** 2031-07-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06948786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06948786, "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06948786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*